Skip to main content

Current knowledge in the use of bacteriophages to combat infections caused by Pseudomonas aeruginosa in cystic fibrosis


Pseudomonas aeruginosa (PA) is considered the first causal agent of morbidity and mortality in people with cystic fibrosis (CF) disease. Multi-resistant strains have emerged due to prolonged treatment with specific antibiotics, so new alternatives have been sought for their control. In this context, there is a renewed interest in therapies based on bacteriophages (phages) supported by several studies suggesting that therapy based on lytic phages and biofilm degraders may be promising for the treatment of lung infections in CF patients. However, there is little clinical data about phage studies in CF and the effectiveness and safety in patients with this disease has not been clear. Therefore, studies regarding on phage characterization, selection, and evaluation in vitro and in vivo models will provide reliable information for designing effective cocktails, either using mixed phages or in combination with antibiotics, making a great progress in clinical research. Hence, this review focuses on the most relevant and recent findings on the activity of lytic phages against PA strains isolated from CF patients and hospital environments, and discusses perspectives on the use of phage therapy on the treatment of PA in CF patients.

This is a preview of subscription content, access via your institution.


Download references


This research was supported by Grant number: 102/201112 to Josefina León-Félix. Claudia Villicaña is supported by Cátedras Consejo Nacional de Ciencia y Tecnología (CONACYT) research project 784: “Functional Genomics of organisms for Food and Agriculture to Mexico”.

Author information

Authors and Affiliations



All authors contributed to the conception and design of the study. Josefina León-Félix had the idea for the article and María José Martínez-Gallardo performed the literature search. Data analyzes were carried out by María José Martínez-Gallardo and Claudia Villicaña. The first draft of the manuscript was written by María José Martínez-Gallardo and Josefina León-Félix. Martha Yocupicio-Monroy and Sofía Lizeth Alcaraz-Estrada critically revised the work. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Josefina León-Félix.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Martínez-Gallardo, M.J., Villicaña, C., Yocupicio-Monroy, M. et al. Current knowledge in the use of bacteriophages to combat infections caused by Pseudomonas aeruginosa in cystic fibrosis. Folia Microbiol (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Pseudomonas aeruginosa
  • Bacteriophage
  • Cystic fibrosis
  • Multi-resistant strains
  • Phage therapy